## Lead Time Bias: Definition and Mechanism **Key Point:** Lead time bias occurs when screening detects disease earlier in its natural history without actually prolonging survival or improving outcomes. The apparent improvement in survival time is an artifact of earlier detection, not true benefit. ### How Lead Time Bias Works Consider a disease with a natural history from onset to death of 10 years: - **Without screening:** Disease detected at year 5 → patient survives 5 more years (total "survival" = 5 years from diagnosis) - **With screening:** Disease detected at year 2 → patient survives 5 more years (total "survival" = 8 years from diagnosis) Survival time appears to improve by 3 years, but the patient dies at the same absolute time. The extra 3 years is merely the "lead time" — the earlier detection point. ### Clinical Significance **High-Yield:** Lead time bias is a critical limitation of screening programs. It can make ineffective screening appear beneficial if only survival time from diagnosis is measured, rather than mortality rate or quality of life. **Clinical Pearl:** To avoid lead time bias, screening efficacy should be evaluated using: - Mortality rates (deaths per 1000 population) — not survival time from diagnosis - Incidence rates in screened vs. unscreened populations - Quality-adjusted life years (QALYs) ### Example in Practice A screening program for prostate cancer using PSA may detect cancers years earlier, improving "5-year survival" statistics, but may not reduce overall mortality or improve health outcomes — a classic example of lead time bias in modern screening. [cite:Park 26e Ch 10]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.